Telix Pharmaceuticals Agrees to Acquire ITM Isotope Technologies Munich for US$1.65 Billion

Reuters explicitly reports that Telix Pharmaceuticals agreed to acquire Germany-based ITM Isotope Technologies Munich for approximately US$1.65 billion, including approximately US$1.25 billion in Telix shares after adjustments. This is a new, material transfer of corporate control with forward implications for Telix’s radiopharmaceutical platform, isotope supply chain, financing and competitive positioning, so it qualifies as a high-importance merger-and-acquisition development rather than market-performance commentary. Surprise is set below the highest range because no prior market expectations or rumors are provided. The exact real-world announcement time is not stated; the timestamp is retained as the best UTC estimate based on the wire timing and the Monday, September 21, 2026 announcement date referenced in the supplementary context. The supplementary source also explicitly describes contingent consideration of up to US$700 million and customary closing conditions. The prior classification as a distinct new event is retained because this acquisition is separate from ITM-11’s regulatory review and Telix’s other disclosed collaborations. Approved stakeholders are limited to the direct acquirer, an explicitly exposed competing radiopharmaceutical company, and a company with a stated ITM isotope-supply dependency; generic industry peers and service providers are omitted.